GlassScriptPhysician profile
Colleen Macinnis
NPI 1700828290
$347.65
in general payments reported to CMS, 2019-2025
11 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.46 · 2020: $53.79 · 2021: $48.61 · 2023: $69.33 · 2024: $23.72 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $226.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $61.27 | 2025 | Daxxify |
| Kerecis Limited | $51.94 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Galderma Laboratories, L.P. | $48.61 | 2021 | |
| Abbvie INC. | $34.04 | 2023 | |
| Amgen INC. | $31.74 | 2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $28.50 | 2025 | |
| Sun Pharmaceutical Industries INC. | $24.25 | 2020 | |
| Almirall LLC | $19.30 | 2023 | Klisyri |
| Mayne Pharma Commercial LLC | $18.46 | 2019 | |
| Biofrontera INC. | $16.74 | 2020 | |
| Genentech USA, INC. | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Macinnis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.